Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | EED | O75530 | 5/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 5/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.39 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19620738 | 0.87 | EZH2 (0.54) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL2593834 | 0.81 | EZH2 (0.73) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL19621017 | 0.77 | EZH2 (0.40) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20991985 | 0.75 | EZH2 (0.52) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL19620855 | 0.75 | EZH2 (0.39) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19620823 | 0.73 | EZH2 (0.42) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL19391673 | 0.72 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19621002 | 0.71 | EZH2 (0.46) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL19620816 | 0.71 | EZH2 (0.48) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL18863744 | 0.71 | EZH2 (0.78) | EZH2BRD4EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |